Senescent cells—those that have stopped dividing but remain metabolically active—exist as a diverse collection of cellular phenotypes rather than a single uniform state. This heterogeneity arises from different senescence triggers, cellular origins, and varying molecular markers, compounded by technical differences in experimental models used to study them. The recognition of this complexity fundamentally challenges the current approach to senolytic therapies, which aim to selectively eliminate senescent cells to combat aging and age-related diseases. While senolytics like dasatinib and quercetin have shown promise in early trials, this cellular diversity suggests that different senescent cell populations may require distinct targeting strategies. Some senescent cells may be beneficial in certain contexts, such as wound healing and tissue repair, while others drive pathological aging processes. The field now faces the critical task of developing precision approaches that can distinguish between harmful and beneficial senescent cell populations. This represents a paradigm shift from the original 'kill all senescent cells' strategy toward nuanced interventions that preserve protective cellular senescence while eliminating pathological variants—a far more complex but potentially more effective approach to healthy aging.